Stimcell Energetics, Inc. (STME) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Stimcell Energetics, Inc. (STME) trades at $0.18. Stimcell Energetics, Inc. (STME) is a biotechnology company focused on developing therapeutic and non-therapeutic solutions for various health conditions. Market cap: $3.81M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for STME: STME does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates STME against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
STME: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Stimcell Energetics, Inc. (STME) Healthcare & Pipeline Overview
Stimcell Energetics, Inc. (STME) specializes in innovative biotechnology solutions, particularly the eBalance system, designed to enhance wellness and manage chronic health conditions, positioning itself within the expanding medical devices sector.
What Is the Investment Thesis for STME?
Stimcell Energetics, Inc. is positioned in a niche segment of the healthcare market, focusing on innovative pain management solutions through its eBalance system. The company operates in a sector projected to grow as the demand for non-invasive therapeutic devices increases, driven by an aging population and a rise in chronic health conditions. Key value drivers include the unique microcurrent technology utilized in the eBalance system, which differentiates it from traditional pain relief methods. Additionally, the company's rebranding and focus on market introduction suggest a strategic pivot towards enhancing its visibility and market penetration. However, risks include the challenges of operating as an OTC stock, which may limit access to capital and increase scrutiny from investors. The success of Stimcell Energetics will heavily rely on its ability to secure funding for product development and marketing efforts within the competitive medical devices landscape.
Based on FMP financials and quantitative analysis
STME Key Highlights
Market Cap of $3.81M indicates a small but focused presence in the medical devices sector.
- Beta of 48.49 suggests high volatility, reflecting the risks associated with OTC market listings.
- No dividend yield, indicating a focus on reinvestment in product development rather than shareholder returns.
- Single employee structure may limit operational capacity but allows for streamlined decision-making.
- The eBalance system targets a wide range of health conditions, potentially appealing to a diverse customer base.
Who Are STME's Competitors?
STME is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MDT Medtronic plc | $92.88 | -1.33% | $119B | 77 |
| SYK Stryker Corporation | $340.11 | +0.04% | $131B | 79 |
| BSX Boston Scientific Corporation | $52.01 | +3.05% | $77.3B | 80 |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $2.96 | -1.66% | $19.3M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are STME's Key Strengths?
Innovative product offering with the eBalance system targeting multiple health conditions.
- Small team allows for flexibility and rapid decision-making.
- Established brand identity following rebranding efforts.
What Are STME's Weaknesses?
Limited operational capacity with only one employee.
- Small market capitalization may limit growth potential.
- Lack of established distribution channels compared to larger competitors.
What Could Drive STME Stock Higher?
Expansion of marketing efforts for the eBalance system to increase product visibility.
- Development and refinement of the eBalance product line to meet market demands.
- Potential partnerships with healthcare providers to enhance distribution channels.
- Monitoring of industry trends to adapt product offerings accordingly.
What Are the Key Risks for STME?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges in introducing new products to the market.
- High volatility associated with OTC market trading.
- Competition from established medical device companies with greater resources.
- Limited operational capacity may hinder growth opportunities.
What Are the Growth Opportunities for STME?
- Expansion of eBalance System: The eBalance system is designed to cater to a growing market of individuals seeking alternative pain management solutions. The global pain management market is projected to reach $85 billion by 2027, with increasing demand for non-pharmaceutical options. Stimcell Energetics can capitalize on this trend by expanding its marketing efforts and increasing product availability in healthcare settings.
- Partnerships with Healthcare Providers: Collaborating with healthcare practitioners can enhance the credibility and reach of the eBalance system. By establishing partnerships with clinics and hospitals, Stimcell Energetics can facilitate product trials and gain endorsements from healthcare professionals, driving adoption and sales. This strategy could significantly increase market penetration over the next 2-3 years.
- Development of New Product Lines: Stimcell Energetics has the opportunity to innovate further within the medical devices sector by expanding its product offerings beyond the eBalance system. Developing complementary products that address other health conditions could tap into additional market segments, potentially increasing revenue streams over the next 5 years.
- Increased Focus on Wellness: As consumer awareness of health and wellness grows, there is a rising demand for products that promote overall well-being. Stimcell Energetics can leverage this trend by marketing the eBalance Home System as part of a holistic wellness approach, appealing to health-conscious consumers looking for non-invasive solutions.
- Geographic Expansion: Stimcell Energetics could explore international markets, particularly in regions with a high prevalence of chronic diseases and a growing acceptance of alternative therapies. Entering markets in Europe and Asia could provide substantial growth opportunities, with the potential to increase sales and brand recognition in the next 3-5 years.
What Are STME's Competitive Advantages?
- Unique microcurrent technology differentiates the eBalance system from competitors.
- Focus on both clinical and home-use applications provides a broader market appeal.
- Established brand recognition following rebranding efforts enhances market positioning.
- Small operational structure allows for agile decision-making and innovation.
- Targeting a growing segment of health-conscious consumers seeking non-invasive solutions.
What Does STME Do?
StimCell Energetics Inc., established in 2010 as Cell MedX Corp., is a biotechnology firm headquartered in Vancouver, Canada. The company focuses on the research, development, and market introduction of therapeutic and non-therapeutic solutions aimed at individuals managing chronic conditions such as diabetes, Parkinson's disease, hypertension, neuropathy, and kidney function issues. In November 2024, the company rebranded to its current name, reflecting its commitment to energizing health solutions. Its flagship product, the eBalance system, consists of two versions: the eBalance Pro System for clinical use by healthcare practitioners and the eBalance Home System for personal use. Both systems operate through the eBalance Console, which features three pre-programmed microcurrent algorithms targeting general wellness, pain relief, and a dual mode for combined benefits. These products aim to provide temporary relief from discomfort in various body areas, including the shoulders, waist, back, neck, arms, and legs. With a small team of just one employee, StimCell Energetics is positioned to leverage its innovative technology in a growing market, addressing the needs of patients seeking alternative solutions for pain management and overall health improvement.
What Products and Services Does STME Offer?
- Develop therapeutic and non-therapeutic solutions for chronic health conditions.
- Offer the eBalance system for pain relief and overall wellness.
- Provide both clinical and home-use versions of their flagship product.
- Utilize microcurrent technology to promote health benefits.
- Target conditions such as diabetes, Parkinson's disease, and hypertension.
- Focus on innovative biotechnology solutions in the medical devices sector.
How Does STME Make Money?
- Generate revenue through the sale of eBalance systems to healthcare practitioners and consumers.
- Leverage partnerships with healthcare providers for product distribution.
- Focus on direct-to-consumer sales for the eBalance Home System.
- Explore potential licensing agreements for proprietary technology.
- Invest in research and development to enhance product offerings and expand market reach.
What Industry Does STME Operate In?
The medical devices industry is experiencing significant growth, driven by advancements in technology and an increasing prevalence of chronic diseases. The global market for medical devices is projected to reach over $600 billion by 2028, with a compound annual growth rate (CAGR) of approximately 5.4%. Within this landscape, companies like Stimcell Energetics, which focus on innovative therapeutic solutions, are well-positioned to capture market share. The competitive landscape includes both established players and emerging startups, emphasizing the need for differentiation through unique product offerings and effective marketing strategies.
Who Are STME's Key Customers?
- Healthcare practitioners seeking innovative pain management solutions for their patients.
- Individuals managing chronic health conditions looking for alternative therapies.
- Wellness-focused consumers interested in non-invasive health solutions.
- Clinics and hospitals looking to incorporate new therapeutic technologies.
- Potential international markets with demand for alternative medical devices.
Key Financial Metrics
Return on equity for Stimcell Energetics, Inc. stands at 60.4%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -5.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -14.1%, the inverse of the P/E and a quick read on earnings relative to price.
Stimcell Energetics, Inc. (STME) Valuation Context
Valued at $3.81M, STME is classified as a micro-cap stock.
Company Profile
Stimcell Energetics, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO David Jeffs. STME has traded publicly since 2013.
Financial Health
Stimcell Energetics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Forward Outlook
Wall Street analysts project Stimcell Energetics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.04.
Insider Activity
The most recent 12 insider filings for Stimcell Energetics, Inc. break down as 2 sales and 10 purchases. On net that is roughly 194.5M shares disposed (about $788K), a signal worth weighing alongside the fundamentals.
STME Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative product offering with the eBalance system targeting multiple health conditions.
- Small team allows for flexibility and rapid decision-making.
- Established brand identity following rebranding efforts.
- Upcoming: Expansion of marketing efforts for the eBalance system to increase product visibility.
Bear Case
- Limited operational capacity with only one employee.
- Small market capitalization may limit growth potential.
- Lack of established distribution channels compared to larger competitors.
- Potential: Regulatory challenges in introducing new products to the market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
STME Latest News
No recent news available for STME.
STME Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for STME.
Price Targets
Wall Street price target analysis for STME.
STME MoonshotScore
What does this score mean?
The MoonshotScore rates STME 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: David Jeffs
CEO
David Jeffs has been leading Stimcell Energetics, Inc. since its inception in 2010, bringing extensive experience in the biotechnology sector. He has a background in both science and business, which has equipped him with the skills necessary to navigate the complex landscape of medical devices. Jeffs has a proven track record in product development and market introduction, having successfully transitioned the company from its original identity as Cell MedX Corp. to its current focus on innovative health solutions.
Track Record: Under David Jeffs' leadership, Stimcell Energetics has rebranded and positioned itself to capture a growing market in the healthcare sector. His strategic decisions have focused on enhancing product visibility and expanding the company's reach within therapeutic markets.
STME OTC Market Information
The OTC Other tier indicates that Stimcell Energetics, Inc. operates in a less regulated environment compared to major exchanges like NYSE or NASDAQ. This tier is characterized by lower reporting requirements, which can lead to increased risk for investors due to less transparency and oversight.
- OTC Tier: OTC Other
- Limited regulatory oversight may expose investors to higher risks.
- Potential for lower liquidity compared to stocks on major exchanges.
- Increased scrutiny from investors due to the company's small size and operational capacity.
- Verify the company's financial health and recent performance.
- Examine the product pipeline and development timelines.
- Assess the competitive landscape and market positioning.
- Research management's track record and strategic vision.
- Evaluate potential risks associated with OTC trading.
- Established history since 2010, indicating operational stability.
- Recent rebranding efforts to enhance market presence.
- Focus on innovative solutions in a growing healthcare market.
Stimcell Energetics, Inc. Healthcare Stock: Key Questions Answered
What does Stimcell Energetics, Inc. do?
Stimcell Energetics, Inc. is a biotechnology company focused on developing innovative therapeutic and non-therapeutic solutions for chronic health conditions. Its primary product, the eBalance system, offers both clinical and home-use versions that utilize microcurrent technology to promote wellness and alleviate pain for individuals managing conditions such as diabetes and Parkinson's disease.
What are the main risks for STME?
Stimcell Energetics, Inc. faces several risks, including the challenges of operating as an OTC stock, which may limit access to capital and increase scrutiny from investors. Additionally, the company competes with larger medical device firms that have more resources and established market presence. Regulatory hurdles in bringing new products to market and the high volatility associated with OTC trading further compound these risks.
How does Stimcell Energetics, Inc. manage patent expiration risks?
Stimcell Energetics, Inc. must proactively manage patent expiration risks by focusing on continuous innovation and developing a robust pipeline of new products. This includes investing in research and development to enhance existing technologies and exploring new therapeutic areas. By maintaining a competitive edge through innovation, the company can mitigate the impact of patent expirations on its market position.
What are the key factors to evaluate for STME?
Evaluate STME on fundamentals, analyst consensus, and risk factors. Stimcell Energetics, Inc. is positioned in a niche segment of the healthcare market, focusing on innovative pain management solutions through its eBalance system. Not financial advice.
How frequently does STME data refresh on this page?
STME's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven STME's recent stock price performance?
Stimcell Energetics, Inc. (STME) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offering with the eBalance system targeting multiple health conditions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider STME overvalued or undervalued right now?
Stimcell Energetics, Inc. (STME) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research STME before investing?
Before investing in Stimcell Energetics, Inc. (STME), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial disclosures available due to OTC classification.